[feed] Atom [feed] RSS 1.0 [feed] RSS 2.0

Rakesh Sathish, Nair and Veena , Somasundaram and Sreelatha K., Hemalatha and Satheesh Kumar , Sengodan and Revathy, Nadhan and Priya, Srinivas (2016) Increased sensitivity of BRCA defective triple negative breast tumors to plumbagin through induction of DNA Double Strand Breaks (DSB). Scientific Reports, 6. ISSN ISSN 2045-2322

[img] Text
Increased senitivity (Sci Reports).pdf
Restricted to Registered users only

Download (1862Kb) | Request a copy
[img] Text
Increased senitivity (Sci Reports).pdf

Download (1862Kb)


We have earlier shown that Plumbagin (PB) can induce selective cytotoxicity to BRCA1 defective ovarian cancer cells; however, the effect of this molecule in BRCA1 mutated breast cancers has not been analyzed yet. Here, we report that reactive oxygen species (ROS) induced by PB resulted in DNA DSB and activates downstream signaling by ATR/ATM kinases and subsequent apoptosis. PB reduces DNA- dependent protein kinase (DNA-PK) expression and inhibits NHEJ (Non Homologous End Joining) activity in BRCA1 defective breast cancer cells. Also, PB induces apoptosis in two different BRCA1 conditional knock out murine models: MMTV-Cre; BRCA1Co/Co and WAP-Cre; BRCA1Co/Co, at 2 mg/kg body weight, but 32 mg/kg of carboplatin (CN) was needed to induce apoptosis in them. This is the first study where two different tissue specific promoter driven transgenic mice models with BRCA1 exon 11 deletions are used for preclinical drug testing. The apoptosis induced by PB in HR (Homologous Recombination) defective triple negative BRCA1 mutant cell lines and in mouse models occur by inducing ROS mediated DNA DSB. The toxicity profile as compared with CN in transgenic mice provides evidence for PB’s safer disposition as a therapeutic lead in breast cancer drug development.

Item Type: Article
Subjects: Cancer Research
Depositing User: Rgcb Library
Date Deposited: 17 Mar 2017 07:29
Last Modified: 17 Mar 2017 07:29
URI: http://rgcb.sciencecentral.in/id/eprint/303

Actions (login required)

View Item View Item